



Article

Application of a Novel Algorithm for Expanding Newborn Screening for Inherited Metabolic Disorders across Europe

Simon A. Jones¹, David Cheillan², Anupam Chakrapani³, Heather J. Church¹, Simon Heales⁴,
Teresa H. Y. Wu¹ , Georgina Morton⁵, Patricia Roberts⁵, Erica F. Sluys⁶ and Alberto Burlina^{7,*}

- ¹ Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, St Mary's Hospital, Oxford Road, Manchester M13 9WL, UK; simon.jones@mft.nhs.uk (S.A.J.); heather.church@mft.nhs.uk (H.J.C.); hoyee.wu@mft.nhs.uk (T.H.Y.W.)
- ² Service Biochimie et Biologie Moléculaire, Groupement Hospitalier Est, Hospices Civils de Lyon, 69002 Lyon, France; david.cheillan@chu-lyon.fr
- ³ Department of Metabolic Medicine, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK; anupam.chakrapani@gosh.nhs.uk
- ⁴ Neurometabolic Unit, University College London Hospitals NHS Foundation Trust and Enzymes Laboratory, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK; simon.heales@gosh.nhs.uk
- ⁵ ArchAngel MLD Trust, Registered Charity No. 1157825, 59 Warwick Square, London SW1V 2AL, UK; georginamorton@archangel.org.uk (G.M.); patroberts.nbs@archangel.org.uk (P.R.)
- ⁶ Helvet Health, Ruelle de la Muraz 4, 1260 Nyon, Switzerland; e.sluys@helvet-group.com
- ⁷ Division of Inherited Metabolic Diseases, Reference Centre Expanded Newborn Screening, University Hospital Padova, 35128 Padova, Italy
- * Correspondence: alberto.burlina@unipd.it



Citation: Jones, S.A.; Cheillan, D.; Chakrapani, A.; Church, H.J.; Heales, S.; Wu, T.H.Y.; Morton, G.; Roberts, P.; Sluys, E.F.; Burlina, A. Application of a Novel Algorithm for Expanding Newborn Screening for Inherited Metabolic Disorders across Europe. *Int. J. Neonatal Screen.* **2022**, *8*, 20. <https://doi.org/10.3390/ijns8010020>

Academic Editor: Lennart Hammarström

Received: 25 November 2021

Accepted: 28 February 2022

Published: 15 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Inherited metabolic disorders (IMDs) are mostly rare, have overlapping symptoms, and can be devastating and progressive. However, in many disorders, early intervention can improve long-term outcomes, and newborn screening (NBS) programmes can reduce caregiver stress in the journey to diagnosis and allow patients to receive early, and potentially pre-symptomatic, treatment. Across Europe there are vast discrepancies in the number of IMDs that are screened for and there is an imminent opportunity to accelerate the expansion of evidence-based screening programmes and reduce the disparities in screening programmes across Europe. A comprehensive list of IMDs was created for analysis. A novel NBS evaluation algorithm, described by Burlina et al. in 2021, was used to assess and prioritise IMDs for inclusion on expanded NBS programmes across Europe. Forty-eight IMDs, of which twenty-one were lysosomal storage disorders (LSDs), were identified and assessed with the novel NBS evaluation algorithm. Thirty-five disorders most strongly fulfil the Wilson and Jungner classic screening principles and should be considered for inclusion in NBS programmes across Europe. The recommended disorders should be evaluated at the national level to assess the economic, societal, and political aspects of potential screening programmes.

Keywords: newborn screening (NBS); inherited metabolic disorder (IMD); public health; genetics; congenital disorder; lysosomal storage disorder (LSD); inborn errors of metabolism; rare diseases; methodology; algorithm

1. Introduction

Inherited metabolic disorders (IMDs) are a large class of rare genetic disorders. IMDs are defined as any primary genetic condition in which alteration of a biochemical pathway is intrinsic to specific biochemical, clinical and/or pathophysiological features [1]. Accurate and timely diagnosis is essential for patients with IMDs, because for many IMDs, treatment (including diet) is available that may improve outcomes. However, many patients face difficulty in obtaining an accurate and timely diagnosis because of the number of rare genetic disorders and the heterogeneity of symptoms and phenotypes [2]. It is possible to carry out widespread, routine screening of many IMDs using dried blood spot (DBS) tests.

Furthermore, tandem mass spectrometry (MS/MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) have drastically advanced screening capabilities. One DBS can now be analysed for an increasing number of disorders, allowing for the expansion of newborn screening (NBS) programmes [3,4].

In the United States (US), the Recommended Uniform Screening Panel (RUSP) has allowed for expansion and standardisation of NBS across states. While in Europe there are some countries screening newborns for over 20 disorders—such as Italy, Hungary, or Austria—other countries screen newborns for as few as two disorders [4]. In 2016 in Italy, legislation was passed that every child born should have the right to be screened for almost 40 IMDs for which there is a viable treatment [5]. Following this bold legislation, in 2019, the European Union (EU) Parliament welcomed the introduction of the “Italian model” and a discussion on how this model might be adopted by all EU member states. Yet, despite the willingness to come together across Europe and harmonise NBS programmes [4,6,7], great disparities exist within the EU and there is no uniform approach for expanding NBS.

With the desire to pave the way forward for evidence-based expansion of NBS programmes, a new approach to objectively evaluate and prioritise IMDs for inclusion in NBS programmes was recently proposed in the form of an algorithm [8]. This algorithm was developed based on the Wilson and Jungner classic screening principles [9]. With the NBS evaluation algorithm, it is possible to prioritise disorders for inclusion on screening programmes, utilising objective and measurable criteria. Individual countries could then strategically evaluate prioritised disorders for inclusion in their NBS programmes based on local economic, societal, and political considerations. The algorithm is intended to offer an objective and standardised tool to evaluate disorders for inclusion on NBS programmes.

The objective of this work is to evaluate and rank a comprehensive list of IMDs using the NBS evaluation algorithm, as described in a previous paper by the authors [8].

2. Methods

2.1. Identification of Disorders for Analysis

A three-step process was used to select which IMDs would be analysed with the NBS evaluation algorithm (see Figure 1). First, we identified the 84 disorders that were initially considered by the US working group to develop the RUSP in Watson MS et al. [10]. Next, we used the Genetic and Rare Diseases (GARD) Database to validate sixty-seven IMDs. Lastly, 48 IMDs were selected for analysis, based on the following three criteria to advantage disorders that are already widely screened for or that have previously been recommended for screening: (1) The disorder is included in the US RUSP Core Conditions or Secondary Conditions list. (2) The disorder is screened for in the following eight countries, that have a similar healthcare expenditure per capita and who screen for over six IMDs: Germany, Sweden, Austria, Australia, Iceland, New Zealand, Italy, and Portugal [11]. (3) The disorder was recommended for screening in one of three peer-reviewed publications [7,12,13] or by the EU Network of Experts on NBS [6].

2.2. Assessment of Inherited Metabolic Disorders

The NBS evaluation algorithm [8] was used to assess, score, and rank the 48 IMDs. This algorithm is built based on the Wilson and Jungner classic screening principles [9], and consists of three pillars, Condition, Screening and Treatment. Each pillar contains specific weighted criteria to evaluate disorders; for Condition a maximum of 6 points, for Screening a maximum of 3 points, and for Treatment a maximum of 4 points can be attributed, see Figure 2. Each IMD was analysed using the currently available scientific evidence, including peer-reviewed publications, published databases, and national or international screening databases.




Figure 1. Selection of disorders for analysis [8–10,13,14].

Condition (score range [0–6])		Screening (score range [0–3])		Treatment (score range [0–4])							
Severity	The disorder only has severe forms	0.5	AND	Availability	DBS test is available and in use	2	OR	Availability	An EMA-approved treatment is available	1.5	OR
	There is a rapidly progressing form	0.5			DBS test is not yet available, but is in development with published evidence	1			A treatment intervention is available (diet, HSCT, BMT)	1	
	The disorder can be fatal by adolescence	1		Performance	DBS test has a low false-positive rate and/or a high PPV	1	A treatment is in late development (phase 3)		1		
Onset	All forms of the disorder are asymptomatic for the first few weeks of life	1	OR		DBS test has a high false-positive rate and/or a low PPV and/or requires additional confirmatory strategies that are available to improve screening performance	0.5	A treatment is in early development (preclinical, phase 1, or phase 2)		0.5		
	More than 50% of cases are an early-onset phenotype	1		Outcomes	OR	The treatment strategy changes the prognosis for all forms of the disorder	1.5	OR			
Frequency	Greater than or equal to 1 in 50,000	2	OR			The treatment strategy changes the prognosis for some forms of the disorder	1				
	Greater than or equal to 1 in 100,000 and less than 1 in 50,000	1.5				The treatment strategy does not change prognosis or improves only some symptoms of the disorder	0.5				
	Greater than or equal to 1 in 150,000 and less than 1 in 100,000	1			AND	Pre-symptomatic initiation results in better outcomes	1				
	Between 1 in 250,000 and 1 in 150,000	0.5									

Figure 2. NBS evaluation algorithm [8].

Condition: Information on the natural history and frequency of each IMD was gathered from the following references, sequentially checked in June 2021: GARD database, Orphanet portal, MedlinePlus, and PubMed for relevant peer-reviewed publications. For the frequency of the disorder, European birth prevalence or incidence was used preferentially, and worldwide or US data were used as an alternative when European evidence was lacking (see Table A1 in Appendix A).

Screening: Any disorder that is included in a public DBS NBS programme, or that has a registered Conformité Européenne (CE) marked or Food and Drug Administration (FDA) approved DBS assay was assigned two points for the *Screening* “Availability” category. For

disorders where this was not the case, further research was performed using PubMed to find any relevant published evidence of a DBS test in development. PubMed was also used to find performance data of the DBS tests, determining if the DBS test had a low false-positive rate by itself or if additional confirmatory strategies were required and available to improve screening performance, such as second-tier enzyme activity tests performed on the same blood spot or multivariate pattern recognition software.

Treatment: A stepwise approach was used to assess the *Treatment* “Availability” category. First, the European Medicines Agency (EMA) website was used to search for approved treatments. If no approved treatment was found, a search was performed on the [ClinicalTrials.gov](https://clinicaltrials.gov) database to identify investigational treatments in phase III development. Peer-reviewed publications were identified which documented other available treatment interventions such as diet, hematopoietic stem cell transplantation (HSCT), or bone marrow transplant (BMT). In this paper, “treatment strategy” includes both EMA-approved and in development treatments, and treatment interventions (such as diet, BMT or HSCT). Only the highest-scoring treatment strategy was used to assess the *Treatment* “Outcomes” category. For the pre-symptomatic initiation of treatment criterion, no score was given if there was no available clinical data.

Total scores were obtained by adding up the sub-scores for each pillar of the algorithm. The IMDs were then ranked based on their total scores (see Table 1).

Table 1. Scoring of IMDs using the IMD NBS evaluation algorithm, ranked by highest to lowest score.

Disorder	Score (0–13)	Condition			Screening		Treatment	
		Severity	Onset	Frequency	Availability	Performance	Availability	Outcomes
Carnitine uptake defect/carnitine transport defect (CUD)	12.5	1.5	2	2	2	1	1.5	2.5
Severe combined immunodeficiency (SCID)	12	2	2	2	2	0.5	1.5	2
Glutaric aciduria type 1 (GA1)	11.5	2	2	1.5	2	1	1	2
Homocystinuria (HCU)	11.5	1.5	2	1	2	1	1.5	2.5
Phenylketonuria (PKU)	11.5	0.5	2	2	2	1	1.5	2.5
Tyrosinemia, type 1 (TYR 1)	11.5	1.5	2	1.5	2	0.5	1.5	2.5
Classic galactosaemia (GALT)	11	2	1	2	2	1	1	2
3-Hydroxy-3-methylglutaric aciduria (HMG)	11	1.5	2	1	2	1	1	2.5
Pompe disease	11	1.5	1	2	2	0.5	1.5	2.5
X-linked adrenoleukodystrophy (X-ALD)	10.5	1.5	1	2	2	1	1	2
Argininosuccinic aciduria (ASA)	10.5	2	1	1.5	2	1	1.5	1.5
Carnitine palmitoyltransferase, type I deficiency (CPT I)	10.5	2	2	0	2	1	1	2.5
Long-chain 3 hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)	10.5	2	2	1	2	1	1	1.5
Methylmalonic acidemia (cobalamin disorders, Cbl A, B)	10.5	2	2	0	2	1	1	2.5
Metachromatic leukodystrophy (MLD)	10.5	2	2	1.5	1	0.5	1.5	2
Mucopolysaccharidosis, type I (MPS I)	10.5	1.5	2	1.5	2	0.5	1.5	1.5
Propionic acidemia (PROP)	10.5	2	1	0.5	2	1	1.5	2.5
Biotinidase deficiency (BIOT)	10.5	2	1	1.5	2	0.5	1	2.5
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	10	1.5	1	2	2	1	1	1.5
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)	10	1.5	1	2	2	1	1	1.5
Citrullinemia, type I (CIT)	10	1.5	1	0.5	2	1	1.5	2.5

Table 1. Cont.

Disorder	Score (0–13)	Condition			Screening		Treatment	
		Severity	Onset	Frequency	Availability	Performance	Availability	Outcomes
Holocarboxylase synthetase deficiency (MCD)	10	2	1	0.5	2	1	1	2.5
Krabbe disease	10	1.5	2	1.5	2	0.5	1	1.5
Argininaemia (ARG)	9.5	1.5	2	0	2	0.5	1	2.5
Carnitine acylcarnitine translocase deficiency (CACT)	9.5	2	1	0	2	1	1	2.5
Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)	9.5	1.5	1	2	2	1	1	1
Maple syrup urine disease (MSUD)	9	1.5	0	1	2	1	1	2.5
Methylmalonic acidemia (methylmalonyl-CoA mutase) (MUT)	9	1.5	1	0.5	2	1	1	2
Carnitine palmitoyltransferase, type II deficiency (CPT II)	9	1.5	1	0	2	1	1	2.5
Batten disease (CLN2)	9	2	2	0	1	1	1.5	1.5
Niemann Pick A/B (ASM deficiency)	9	2	2	0.5	2	1	1	0.5
Isovaleric acidemia (IVA)	8.5	1.5	0	1	2	1	1	2
Trifunctional protein deficiency (TFP)	8.5	1.5	1	0	2	1	1	2
Gaucher disease	8.5	1.5	1	1.5	2	0.5	1.5	0.5
Lysosomal acid lipase deficiency (LAL-D/Wolman/CESD)	8.5	1.5	1	0.5	2	1	1.5	1
Multiple acyl-CoA dehydrogenase deficiency (MADD)	8	1.5	0	0.5	2	1	1	2
MPS VI (Maroteaux-Lamy syndrome)	8	1.5	2	0	1	0.5	1.5	1.5
Alpha-mannosidosis	7.5	1.5	1	0	1	1	1.5	1.5
Fabry disease	7.5	0	1	1.5	2	0.5	1.5	1
MPS II (Hunter syndrome)	7	0	2	0.5	1	0.5	1.5	1.5
MPS III (Sanfilippo syndrome)	6.5	0	2	1.5	1	1	0.5	0.5
Niemann-Pick type C disease	6.5	1.5	1	1	1	0	1.5	0.5
MPS IV (Morquio syndrome)	5.5	0	2	0	1	0.5	1.5	0.5
Sandhoff disease (GM2 gangliosidosis, type II)	5.5	1.5	2	1	0	0	1	0
Farber disease	5	2	1	0	0	0	1	1
Tay-Sachs disease (GM2 gangliosidosis, type I)	4.5	1.5	2	0	0	0	1	0
MPS VII (Sly syndrome)	3.5	1.5	0	0	0	0	1.5	0.5
MPS IX (hyaluronidase deficiency)	1	0	1	0	0	0	0	0

3. Results

3.1. Characteristics of IMDs Identified for Analysis

Forty-eight IMDs were selected for evaluation, as described in the Methods section. Table A1 in Appendix A shows some important characteristics of these disorders.

- Twenty-one are lysosomal storage disorders (LSD), eight are disorders of organic acid metabolism (DOAM), seven are disorders of amino acid metabolism (DAAM), nine are disorders of fatty acid metabolism (DFAM), three disorders are classified as Other;
- Nine disorders had a frequency greater than or equal to 1 in 50,000; 10 disorders had a frequency between 1 in 50,000 and 1 in 100,000; seven disorders had a frequency between 1 in 100,000 and 1 in 150,000; eight disorders had a frequency between 1 in 150,000 and 1 in 250,000; 14 disorders had a frequency less than 1 in 250,000;
- Four disorders are screened for in over 20 European countries, 15 disorders are screened for in 11 to 20 European countries, nine disorders are screened for in at least one, but fewer than 10 European countries, and 17 disorders are not screened for in the European countries covered in Castineras DE et al. 2019 [7].

3.2. Scoring and Ranking of IMDs

The 48 IMDs were assessed with the NBS evaluation algorithm and a score was attributed. Table 1 presents the full list of scored disorders ranked by the highest to lowest score (range 0 to 13 points). Burlina et al. proposed a cut-off of 8.5 points and above, based on the validation of the NBS evaluation algorithm with disorders that are already screened for in the United Kingdom NBS screening programme [8]. Using the score of 8.5 as a threshold, there are 35 disorders that most strongly fulfil the Wilson and Jungner classic screening principles and are recommended as candidates for inclusion in NBS programmes across Europe [9].

The highest scoring disorders were carnitine uptake defect/carnitine transport defect (CUD), with a score of 12.5 out of 13, and severe combined immunodeficiency (SCID) with a score of 12. Seven disorders scored 11.5 or 11 points, 14 disorders scored 10.5 or 10 points, nine disorders scored 9.5 or 9 points, and three disorders scored 8.5 points. The remaining 13 disorders scored between 1 and 8 points. Of the 20 LSDs analysed with the NBS evaluation algorithm, eight had a score of 8.5 and higher: Pompe disease, Gaucher disease, lysosomal acid lipase deficiency (LAL-D), metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I (MPS I), Krabbe disease, Batten disease (CLN2), and Niemann Pick A/B (ASM deficiency).

With the NBS evaluation algorithm, it is possible to look separately at each of the three pillars and compare different disorders. Looking at all 48 IMDs assessed, in the pillar *Condition*, 77% of disorders (37/48) received points for “all forms of the disorder are asymptomatic for the first few weeks of life” (see Table A2 in Appendix A). For the pillar *Screening*, 31/48 disorders have a “DBS test available in use”, and 26 of these 31 disorders have a DBS test with a “low false-positive rate or a high positive-predictive value (PPV)” (see Table A3 in Appendix A). For the pillar *Treatment*, 21/48 disorders have an available EMA-approved treatment and 65% of disorders (31/48) have a treatment strategy (either an EMA-approved treatment or a treatment intervention) that results in better outcomes if initiated pre-symptomatically (see Table A4 in Appendix A).

It is also interesting to compare the three pillars of the NBS evaluation algorithm for the 35 top-ranked disorders, those scoring ≥ 8.5 points. For the pillar *Condition*, all 35 top-ranked disorders have a rapidly progressing form and all but one disorder, PKU, can be fatal by adolescence (see Table A2 in Appendix A). Looking at the pillar *Screening*, of the 35 top-ranked disorders, 33 have a DBS test that is available and in use, and of these 33 DBS tests, 25 have a “low false-positive rate or a high PPV” (see Table A3 in Appendix A). For the pillar *Treatment*, 97% (34/35 disorders) have a treatment strategy available, either an EMA-approved treatment (14/34 disorders) or a treatment intervention (20/34 disorders) (see Table A4 in Appendix A). One disorder, Niemann Pick A/B (ASM deficiency), has a treatment in late-stage development. Importantly, 60% (21/35) of the top-ranked disorders have a treatment strategy available that changes the prognosis for all forms (mild to severe) of the disorder. Alternatively, none of the 13 lower ranked disorders (those scoring < 8.5 points) have a treatment strategy available that changes the prognosis for all forms of the disorder. Looking at all three pillars together, we can see that more than half, 54% (19/35 disorders), meet the following three criteria: (1) “all forms of the disorder are asymptomatic for the first weeks of life”; (2) have a “DBS test available and in use”; and (3) have a treatment strategy where “pre-symptomatic initiation results in better outcomes”.

4. Discussion

Currently, in the EU, there are great disparities in the number of disorders screened for between countries. Since 2011, when the European Commission published documentation that supports discussion on how to develop policies for NBS for rare disorders, there has been little concrete progress [6]. The NBS evaluation algorithm [8] could be utilised to objectively assess disorders and build a standard minimal panel of disorders to be recommended for NBS across Europe. Utilising the NBS evaluation algorithm to assess 48 IMDs, there are 35 disorders that most strongly fulfil the Wilson and Jungner classic screening principles and are therefore recommended for inclusion in NBS programmes.

Of these 35 top-ranking disorders, all have a rapidly progressing form, 33 have a DBS test available, and 31 have a treatment strategy available.

We need leadership to drive a consistent and methodological approach for NBS programmes across Europe. The majority of the European member states have no legislation governing NBS [5], but certain European countries have their own particular strengths in NBS. In Italy, since 2016, NBS has been legally mandated throughout the country for about 40 IMDs [5]. The United Kingdom national screening committee (UK NSC), established in 1996, has a rigorous evidence review process and meets three times a year to make new recommendations or update existing ones [14]. The Netherlands NBS programmes is very reactive; SCID was added to their NBS panel in under six years [15]. In April 2015, SCID was recommended for inclusion on NBS, in April 2018 the first heel prick blood was collected on 1 April 2018, and on 1 January 2021 SCID was officially added to the national heel prick screening program [15]. In comparison, the timeline for implementing SCID NBS stretched over a 12 year-period in the US, from 2006 when it was nominated for addition to the RUSP, to 2008 when pilots began in Massachusetts and Wisconsin, to 2018 when all 50 states had implemented NBS for SCID. We need to combine the breadth of disorders on the Italian NBS panel, with the rigor of the UK NSC and the agility of the Dutch programme.

Expanding screening for IMDs at birth has the potential to reduce the time to diagnosis, and the related psychological impact on families and patients, and to allow for early, pre-symptomatic treatment that may change prognosis. NBS programmes also benefit society and the healthcare system because increased patient identification increases our knowledge on natural history, frequency, and genotype/phenotype correlations, and thus can help to advance diagnosis and treatment options [16].

This paper is intended to present a living list of IMDs that, at present, most strongly fulfil objective and measurable clinical criteria, thereby recommending them for further evaluation for inclusion on national NBS programmes. Nevertheless, to accelerate NBS expansion it is critical that countries work together to leverage each other's success and evidence, especially in the rare disease space because of the severity and rapid progression inherent to so many of these disorders. There are disorders that can be accurately diagnosed via DBS test and have a treatment strategy that can change prognosis if initially pre-symptomatically. We need to expand NBS programmes now to diagnose and treat patients earlier.

Author Contributions: Conceptualization, G.M. and P.R.; methodology, E.F.S., G.M. and P.R.; validation, A.B., A.C., D.C., E.F.S., G.M., H.J.C., P.R., S.H., S.A.J. and T.H.Y.W.; formal analysis, A.B., A.C., D.C., E.F.S., G.M., H.J.C., P.R., S.H., S.A.J. and T.H.Y.W.; investigation/review, A.B., A.C., D.C., E.F.S., G.M., H.J.C., P.R., S.H., S.A.J. and T.H.Y.W.; data curation, E.F.S.; writing—original draft preparation, E.F.S.; writing—review and editing, A.B., A.C., D.C., E.F.S., G.M., H.J.C., P.R., S.H., S.A.J. and T.H.Y.W.; visualization, E.F.S.; project administration, E.F.S.; funding acquisition, G.M. and P.R. All authors have read and agreed to the published version of the manuscript.

Funding: The authors received no specific funding for this article. Scientific and editorial support, in the form of medical writing, assembling tables and creating high-resolution images based on authors' detailed directions, collating author comments, copyediting, fact checking, and referencing, was provided by Erica F. Sluys of Helvet Health. This assistance was funded by Orchard Therapeutics. Funding to pay the Open Access publication charges for this article was provided by Orchard Therapeutics.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: ArchAngel MLD Trust for the inception of this work, Charlotte Chanson and Annamarie Dillon of Orchard Therapeutics for their support in coordinating and supporting the expert group during the whole project.

Conflicts of Interest: The authors declare no conflict of interest. ArchAngel MLD Trust, Helvet Health and Orchard Therapeutics had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Table A1. Characteristics of IMDs identified for analysis.

Disorder	Abbreviation	Type of Disorder	Frequency	Gene(s) Involved	European Countries with NBS Programme
3-Hydroxy-3-methylglutaric aciduria	HMG/3HMG	DOAM	1/125,000–1/1,000,000	<i>HMGCL</i> (locus: 1p36.11)	Hungary, Iceland, Italy, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia
3-Methylcrotonyl-CoA carboxylase deficiency	3MCC	DOAM	1/30,000–1/50,000 in Europe	<i>MCCC1</i> , <i>MCCC2</i> (loci: 3q27.1, 5q13.2)	Austria, Hungary, Iceland, Italy, Macedonia, Netherlands, Poland, Portugal, Slovakia, Slovenia
Alpha-mannosidosis	α -mannosidosis	LSD	1/500,000	<i>MAN2B1</i> (locus: 19p13.2-q12)	No screening programmes °
Argininaemia	ARG	DAAM	1/300,000–1/1,000,000 +	<i>ARG1</i> (locus: 6q23.2)	Austria, Czech Republic, Estonia, Finland, Iceland, Italy, Macedonia, Poland, Portugal, Slovakia, Sweden
Argininosuccinic aciduria	ASA	DAAM	1/70,000 [17]	<i>ASL</i> (locus: 7q11.21)	Austria, Denmark, Finland, Hungary, Iceland, Italy, Macedonia, Poland, Portugal, Sweden
Batten disease	CLN2	LSD	Unknown, 1/25,000–1/50,000 for all NCLs [18]	<i>CLN2</i> also known as <i>TPP1</i> (locus: 11p15.4)	No screening programmes °
Biotinidase deficiency	BIOT/BIO/BTD	Other	1/60,000	<i>BTD</i> (locus: 3p25.1)	Austria, Belgium (Flemish), Belgium (Walloon), Czech Republic, Denmark, Germany, Hungary, Italy, Latvia, Liechtenstein, Netherlands, Norway, Poland, San Marino, Spain, Sweden, Switzerland, Turkey
Carnitine acylcarnitine translocase deficiency	CACT	DFAM	Less than 60 cases worldwide	<i>SLC25A20</i> (locus: 3p21.31)	Austria, Czech Republic, Estonia, Finland, Germany, Hungary, Iceland, Italy, Macedonia, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden
Carnitine palmitoyltransferase, type I deficiency	CPT I/CPT1A	DFAM	1/750,000–1/2,000,000 [19]	<i>CPT1A</i> (locus: 11q13.3)	Austria, Czech Republic, Estonia, Finland, Germany, Hungary, Iceland, Italy, Macedonia, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden
Carnitine palmitoyltransferase, type II deficiency	CPT II	DFAM	300 cases reported	<i>CPT2</i> (locus: 1p32.3)	Austria, Czech Republic, Estonia, Finland, Germany, Hungary, Iceland, Italy, Macedonia, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden

Table A1. Cont.

Disorder	Abbreviation	Type of Disorder	Frequency	Gene(s) Involved	European Countries with NBS Programme
Carnitine uptake defect/carnitine transport defect	CUD	DFAM	1/20,000–1/70,000 in Europe	<i>SLC22A5</i> (locus: 5q23.3)	Austria, Croatia, Denmark, Estonia, Finland, Hungary, Iceland, Italy, Macedonia, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden
Citrullinemia, type I	CIT/CTLN1	DAAM	1/250,000 [20]	<i>ASS1</i> (locus: 9q34.11)	Austria, Czech Republic, Estonia, Finland, Hungary, Iceland, Italy, Macedonia, Poland, Portugal, Slovakia, Sweden
Classic galactosaemia	GALT/GAL	Other	1/40,000–1/60,000 in Western countries	<i>GALT</i> (locus: 9p13.3)	Austria, Belgium (Walloon), Denmark, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Liechtenstein, Netherlands, Russia, San Marino, Spain, Sweden, Switzerland
Fabry disease	GLA	LSD	1/80,000	<i>GLA</i> (locus: Xq22)	No screening programmes °
Farber disease	ACD	LSD	200 cases reported worldwide	<i>ASAHI</i> (locus: 8p22)	No screening programmes °
Gaucher disease	GD	LSD	1/50,000–1/100,000 +	<i>GBA</i> (locus: 1q22)	No screening programmes °
Glutaric aciduria type 1	GA1	DOAM	1/100,000	<i>GCDH</i> (locus: 19p13.2)	Austria, Belgium (Flemish), Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Ireland, Italy, Macedonia, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom (UK)
Holocarboxylase synthetase deficiency	MCD/HCS	DOAM	1/200,000	<i>HLCS</i> (locus: 21q22.1)	Austria, Denmark, Hungary, Iceland, Italy, Macedonia, Netherlands, Norway, Portugal, Slovenia
Homocystinuria	HCU/HCY	DAAM	1/150,000 [21]	<i>CBS</i> also <i>MTHFR</i> , <i>MTR</i> , <i>MTRR</i> and <i>MMADHC</i> (loci: 21q22.3, 1p36.22, 1q43, 5p15.31, 2q23.2) *	Austria, Belgium (Walloon), Czech Republic, Estonia, Finland, Hungary, Iceland, Ireland, Italy, Macedonia, Netherlands, Norway, Poland, Portugal, Sweden, UK

Table A1. Cont.

Disorder	Abbreviation	Type of Disorder	Frequency	Gene(s) Involved	European Countries with NBS Programme
Isovaleric acidaemia	IVA	DOAM	1/120,000 [22]	<i>IVD</i> (locus: 15q15.1)	Austria, Belgium (Flemish), Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Italy, Macedonia, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden, UK
Krabbe disease	GLD	LSD	1/100,000 in Northern Europe	<i>GALC</i> (locus: 14q31.3)	Not studied in [4,7,23].
Long-chain 3 hydroxyacyl-CoA dehydrogenase deficiency	LCHAD	DFAM	1/110,000–1/150,000 [24]	<i>HADHA</i> (locus: 2p23.3)	Austria, Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Italy, Macedonia, Netherlands, Norway, Poland, Slovakia, Slovenia, Spain, Portugal, Sweden
Lysosomal acid lipase deficiency	LAL/LAL-D	LSD	1/177,000	<i>LIPA</i> (locus: 10q23.31)	Not studied in [4,7,23].
Maple syrup urine disease	MSUD	DAAM	1/135,000 [22]	<i>BCKDHA</i> , <i>BCKDHB</i> and <i>DBT</i> (loci: 19q13.2, 6q14.1, 1p21.2)	Austria, Belgium (Flemish), Belgium (Walloon), Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Ireland, Italy, Netherlands, Macedonia, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden, Switzerland, UK
Medium-chain acyl-CoA dehydrogenase deficiency	MCAD/MCADD	DFAM	1/4900–1/27,000 in Caucasian population	<i>ACADM</i> (locus: 1p31.1)	Austria, Belgium (Flemish), Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Luxembourg, Macedonia, Norway, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK
Metachromatic leukodystrophy	MLD	LSD	1/40,000–1/160,000 **	<i>ARSA</i> , rarely <i>PSAP</i> (loci: 22q13.33, 10q22.1)	Not studied in [4,7,23].
Methylmalonic acidaemia (cobalamin disorders, Cbl A, B)	MMA/Cbl A,B	DOAM	Over 120 patients with cblA, 66 patients with cblB have been reported	<i>MMAA</i> , <i>MMAB</i> (loci: 4q31.21, 12q24.11)	Austria, Belgium (Flemish), Denmark, Estonia, Finland, Hungary, Iceland, Italy, Macedonia, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Sweden

Table A1. Cont.

Disorder	Abbreviation	Type of Disorder	Frequency	Gene(s) Involved	European Countries with NBS Programme
Methylmalonic acidaemia (methylmalonyl-CoA mutase)	MUT	DOAM	1/167,000 in Europe [25]	<i>MMUT</i> (locus: 6p12.3)	Austria, Belgium (Flemish), Denmark, Hungary, Iceland, Italy, Portugal, Sweden
Mucopolysaccharidosis, type II	MPS II	LSD	1/166,000 in Europe	<i>IDS</i> (locus: Xq28)	No screening programmes °
Mucopolysaccharidosis, type III	MPS III	LSD	1/70,000 in Europe [26]	<i>SGSH, NAGLU, HGSNAT, GNS</i> (loci: 17q25.3, 17q21.2, 8p11.2-p11.1, 12q14.3) *	No screening programmes °
Mucopolysaccharidosis, type IV	MPS IV	LSD	1/77,000–1/1,400,000 in Europe [27]	<i>GALNS</i> for type IV A, <i>GLB1</i> for type IV B (loci: 16q24.3, 3p22.3)	No screening programmes °
Mucopolysaccharidosis, type IX	MPS IX	LSD	Only 4 known cases [28]	<i>HYAL1</i> (locus: 3p21.31)	No screening programmes °
Mucopolysaccharidosis, type VI	MPS VI	LSD	1/43,000–1/1,505,000 [29]	<i>ARSB</i> (locus: 5q14.1)	No screening programmes °
Mucopolysaccharidosis, type VII	MPS VII	LSD	1/345,000–1/5,000,000	<i>GUSB</i> (locus: 7q11.21)	No screening programmes °
Mucopolysaccharidosis, type I	MPS I	LSD	1/100,000	<i>IDUA</i> (locus: 4p16.3)	No screening programmes °
Multiple acyl-CoA dehydrogenase deficiency	MADD	DFAM	1/200,000	<i>ETFA, ETFB, ETFDH</i> (loci: 15q24.2-q24.3, 19q13.41, 4q32.1)	Austria, Belgium (Flemish), Finland, Hungary, Iceland, Italy, Macedonia, Poland, Portugal, Sweden
Niemann-Pick disease, type A/B	ASMD	LSD	1/250,000 +	<i>SMPD1</i> (locus: 11p15.4)	No screening programmes °
Niemann-Pick disease, type C	NPC1 and NPC2	LSD	1/150,000 +	<i>NPC1, NPC2</i> (loci: 18q11.2, 14q24.3)	No screening programmes °

Table A1. Cont.

Disorder	Abbreviation	Type of Disorder	Frequency	Gene(s) Involved	European Countries with NBS Programme
Phenylketonuria	PKU/HPA	DAAM	1/10,000 in Europe	<i>PAH</i> (locus: 12q23.2)	Andorra, Austria, Belarus, Belgium (Flemish), Belgium (Walloon), Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, UK
Pompe disease	GSD 2	LSD	1/40,000 [17]	<i>GAA</i> (locus: 17q25.3)	No screening programmes °
Propionic acidaemia	PROP/PA	DOAM	1/45,000–1/313,000 in Europe [30]	<i>PCCA, PCCB</i> (loci: 13q32.3, 3q22.3)	Austria, Belgium (Flemish), Denmark, Estonia, Finland, Hungary, Iceland, Italy, Macedonia, Netherlands, Norway, Poland, Portugal, Serbia, Slovakia, Slovenia, Sweden
Sandhoff disease (GM2 gangliosidosis, type II)	SD	LSD	1/130,000 in Europe	<i>HEXB</i> (locus: 5q13.3)	No screening programmes °
Severe Combined Immunodeficiency	SCID	Other	1/50,000	must common <i>ADA</i> , also <i>DCLRE1C, IL2RG, IL7R, JAK3, NHEJ1, PTPRC</i> (loci: 20q13.12, 10p13, Xq13, 5p13.2, 19p13.11, 2q35, 1q31.3-q32.1) *	Denmark, Germany, Iceland, Norway, Sweden, Switzerland
Tay-Sachs disease (GM2 gangliosidosis, type I)	TSD	LSD	1/320,000	<i>HEXA</i> (locus: 15q23)	No screening programmes °
Trifunctional protein deficiency	TFP	DFAM	Less than 100 cases reported	<i>HADHA</i> and <i>HADHB</i> (loci: 2p23.3, 2p23.3)	Austria, Denmark, Germany, Hungary, Iceland, Italy, Portugal, Sweden
Tyrosinemia, type 1	TYR 1	DAAM	1/100,000	<i>FAH</i> (locus: 15q25.1)	Austria, Belgium (Walloon), Denmark, Estonia, Finland, Germany, Hungary, Italy, Netherlands, Macedonia, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden

Table A1. Cont.

Disorder	Abbreviation	Type of Disorder	Frequency	Gene(s) Involved	European Countries with NBS Programme
Very long-chain acyl-CoA dehydrogenase deficiency	VLCAD	DFAM	1/25,000 in the European Union [31]	ACADVL (locus: 17p13.1)	Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Italy, Macedonia, Netherlands, Poland, Slovakia, Slovenia, Portugal, Sweden
X-linked adrenoleukodystrophy	X-ALD	Other	1/14,700 [32]	ABCD1 (locus: Xq28)	Netherlands

Type of disorder column: DAAM, Disorders of amino acid metabolism; DFAM, Disorders of fatty acid metabolism; DOAM, Disorders of organic acid metabolism; LSD, lysosomal storage disorder. The classification results from information found in: Loeber et al. (2021) [4], Martínez-Morillo et al. (2016) [17] or Ferreira and Gahl (2017) [33]. Frequency and Gene(s) involved columns: If not noted the source is Orphanet; * Online Mendelian Inheritance in Man; ** National Organization for Rare Disorders; + Medlineplus.gov. European countries with NBS programme column: The countries listed result from information found in: Loeber et al. (2021) [4], Castiñeras et al. (2019) [7] or Therrell et al. (2015) [23]. ° none of the countries studied in Castiñeras et al. (2019) [7] include a screening for this disorder in their programme.

Table A2. Scoring of IMDs using the NBS evaluation algorithm: pillar Condition.

Disorder	Score (0–6)	Condition								
		Severity			Onset			Frequency		
		The Condition Only Has Severe Forms	There Is a Rapidly Progressing Form	The Condition Can Be Fatal by Adolescence	All Forms of the Condition Are Asymptomatic for the First Few Weeks of Life	More than 50% of Cases Are an Early-Onset Phenotype	Greater than or Equal to 1 in 50,000	Greater than or Equal to 1 in 100,000 and Less than 1 in 50,000	Greater than or Equal to 1 in 150,000 and Less than 1 in 100,000	Between 1 in 250,000 and 1 in 150,000
		AND			AND			OR		
		0.5	0.5	1	1	1	2	1.5	1	0.5
Carnitine uptake defect/carnitine transport defect (CUD)	5.5	0	0.5	1	1	1	2	0	0	0
Severe combined immunodeficiency (SCID)	6	0.5	0.5	1	1	1	2	0	0	0
Glutaric aciduria type 1 (GA1)	5.5	0.5	0.5	1	1	1	0	1.5	0	0
Homocystinuria (HCU)	4.5	0	0.5	1	1	1	0	0	1	0
Phenylketonuria (PKU)	4.5	0	0.5	0	1	1	2	0	0	0
Tyrosinemia, type 1 (TYR 1)	5	0	0.5	1	1	1	0	1.5	0	0
Classic galactosaemia (GALT)	5	0.5	0.5	1	0	1	2	0	0	0

Table A2. Cont.

Disorder	Score (0–6)	Condition								
		Severity			Onset			Frequency		
		The Condition Only Has Severe Forms	There Is a Rapidly Progressing Form	The Condition Can Be Fatal by Adolescence	All Forms of the Condition Are Asymptomatic for the First Few Weeks of Life	More than 50% of Cases Are an Early-Onset Phenotype	Greater than or Equal to 1 in 50,000	Greater than or Equal to 1 in 100,000 and Less than 1 in 50,000	Greater than or Equal to 1 in 150,000 and Less than 1 in 100,000	Between 1 in 250,000 and 1 in 150,000
		AND	AND	AND	AND	AND	OR	OR	OR	
		0.5	0.5	1	1	1	2	1.5	1	0.5
3-Hydroxy-3-methylglutaric aciduria (HMG)	4.5	0	0.5	1	1	1	0	0	1	0
Pompe disease	4.5	0	0.5	1	1	0	2	0	0	0
X-linked adrenoleukodystrophy (X-ALD)	4.5	0	0.5	1	1	0	2	0	0	0
Argininosuccinic aciduria (ASA)	4.5	0.5	0.5	1	0	1	0	1.5	0	0
Carnitine palmitoyltransferase, type I deficiency (CPT I)	4	0.5	0.5	1	1	1	0	0	0	0
Long-chain 3 hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)	5	0.5	0.5	1	1	1	0	0	1	0
Methylmalonic acidaemia (cobalamin disorders, Cbl A, B)	4	0.5	0.5	1	1	1	0	0	0	0
Metachromatic leukodystrophy (MLD)	5.5	0.5	0.5	1	1	1	0	1.5	0	0
Mucopolysaccharidosis, type I (MPS I)	5	0	0.5	1	1	1	0	1.5	0	0
Propionic acidaemia (PROP)	3.5	0.5	0.5	1	0	1	0	0	0	0.5
Biotinidase deficiency (BIOT)	4.5	0.5	0.5	1	1	0	0	1.5	0	0
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	4.5	0	0.5	1	1	0	2	0	0	0
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)	4.5	0	0.5	1	1	0	2	0	0	0

Table A2. Cont.

Disorder	Score (0–6)	Condition								
		Severity			Onset			Frequency		
		The Condition Only Has Severe Forms	There Is a Rapidly Progressing Form	The Condition Can Be Fatal by Adolescence	All Forms of the Condition Are Asymptomatic for the First Few Weeks of Life	More than 50% of Cases Are an Early-Onset Phenotype	Greater than or Equal to 1 in 50,000	Greater than or Equal to 1 in 100,000 and Less than 1 in 50,000	Greater than or Equal to 1 in 150,000 and Less than 1 in 100,000	Between 1 in 250,000 and 1 in 150,000
		AND	AND	AND	AND	AND	OR	OR	OR	
		0.5	0.5	1	1	1	2	1.5	1	0.5
Citrullinemia, type I (CIT)	3	0	0.5	1	1	0	0	0	0	0.5
Holocarboxylase synthetase deficiency (MCD)	3.5	0.5	0.5	1	0	1	0	0	0	0.5
Krabbe disease	5	0	0.5	1	1	1	0	1.5	0	0
Argininaemia (ARG)	3.5	0	0.5	1	1	1	0	0	0	0
Carnitine acylcarnitine translocase deficiency (CACT)	3	0.5	0.5	1	0	1	0	0	0	0
Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)	4.5	0	0.5	1	1	0	2	0	0	0
Isovaleric acidaemia (IVA)	2.5	0	0.5	1	0	0	0	0	1	0
Maple syrup urine disease (MSUD)	2.5	0	0.5	1	0	0	0	0	1	0
Methylmalonic acidaemia (methylmalonyl-CoA mutase) (MUT)	3	0	0.5	1	1	0	0	0	0	0.5
Carnitine palmitoyltransferase, type II deficiency (CPT II)	2.5	0	0.5	1	1	0	0	0	0	0
Batten disease (CLN2)	4	0.5	0.5	1	1	1	0	0	0	0
Niemann Pick A/B (ASM deficiency)	4.5	0.5	0.5	1	1	1	0	0	0	0.5
Trifunctional protein deficiency (TFP)	2.5	0	0.5	1	0	1	0	0	0	0
Gaucher disease	4	0	0.5	1	1	0	0	1.5	0	0
Lysosomal acid lipase deficiency (LAL-D/Wolman/CESD)	3	0	0.5	1	1	0	0	0	0	0.5

Table A2. Cont.

Disorder	Score (0–6)	Condition								
		Severity			Onset			Frequency		
		The Condition Only Has Severe Forms	There Is a Rapidly Progressing Form	The Condition Can Be Fatal by Adolescence	All Forms of the Condition Are Asymptomatic for the First Few Weeks of Life	More than 50% of Cases Are an Early-Onset Phenotype	Greater than or Equal to 1 in 50,000	Greater than or Equal to 1 in 100,000 and Less than 1 in 50,000	Greater than or Equal to 1 in 150,000 and Less than 1 in 100,000	Between 1 in 250,000 and 1 in 150,000
		AND	AND	AND	AND	AND	OR	OR	OR	
Multiple acyl-CoA dehydrogenase deficiency (MADD)	2	0	0.5	1	0	0	0	0	0	0.5
MPS VI (Maroteaux-Lamy syndrome)	3.5	0	0.5	1	1	1	0	0	0	0
Alpha-mannosidosis	2.5	0	0.5	1	1	0	0	0	0	0
Fabry disease	2.5	0	0	0	1	0	0	1.5	0	0
MPS II (Hunter syndrome)	2.5	0	0	0	1	1	0	0	0	0.5
MPS III (Sanfilippo syndrome)	3.5	0	0	0	1	1	0	1.5	0	0
Niemann-Pick type C disease	3.5	0	0.5	1	1	0	0	0	1	0
MPS IV (Morquio syndrome)	2	0	0	0	1	1	0	0	0	0
Sandhoff disease (GM2 gangliosidosis, type II)	4.5	0	0.5	1	1	1	0	0	1	0
Farber disease	3	0.5	0.5	1	0	1	0	0	0	0
Tay-Sachs disease (GM2 gangliosidosis, type I)	3.5	0	0.5	1	1	1	0	0	0	0
MPS VII (Sly syndrome)	1.5	0	0.5	1	0	0	0	0	0	0
MPS IX (hyaluronidase deficiency)	1	0	0	0	1	0	0	0	0	0

Table A3. Scoring of IMDs using the NBS evaluation algorithm: pillar *Screening*.

Disorder	Score (0–3)	Screening			
		Availability		Performance	
		DBS Test Is Available and in Use	DBS Test Is Not Yet Available, but Is in Development with Published Evidence	DBS Test Has a Low False-Positive Rate or a High Positive Predictive Value	DBS Test Has a High False-Positive Rate or a Low PPV, or Additional Confirmatory Strategies Are Required That Are Available to Improve Screening Performance
		OR		OR	
		2	1	1	0.5
Carnitine uptake defect/carnitine transport defect (CUD)	3	2	0	1	0
Severe combined immunodeficiency (SCID)	2.5	2	0	0	0.5
Glutaric aciduria type 1 (GA1)	3	2	0	1	0
Homocystinuria (HCU)	3	2	0	1	0
Phenylketonuria (PKU)	3	2	0	1	0
Tyrosinemia, type 1 (TYR 1)	2.5	2	0	0	0.5
Classic galactosaemia (GALT)	3	2	0	1	0
3-Hydroxy-3-methylglutaric aciduria (HMG)	3	2	0	1	0
Pompe disease	2.5	2	0	0	0.5
X-linked adrenoleukodystrophy (X-ALD)	3	2	0	1	0
Argininosuccinic aciduria (ASA)	3	2	0	1	0
Carnitine palmitoyltransferase, type I deficiency (CPT I)	3	2	0	1	0
Long-chain 3 hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)	3	2	0	1	0
Methylmalonic acidaemia (cobalamin disorders, Cbl A, B)	3	2	0	1	0
Metachromatic leukodystrophy (MLD)	1.5	0	1	0	0.5
Mucopolysaccharidosis, type I (MPS I)	2.5	2	0	0	0.5
Propionic acidaemia (PROP)	3	2	0	1	0
Biotinidase deficiency (BIOT)	2.5	2	0	0	0.5
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	3	2	0	1	0
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)	3	2	0	1	0
Citrullinemia, type I (CIT)	3	2	0	1	0
Holocarboxylase synthetase deficiency (MCD)	3	2	0	1	0
Krabbe disease	2.5	2	0	0	0.5
Argininaemia (ARG)	2.5	2	0	0	0.5
Carnitine acylcarnitine translocase deficiency (CACT)	3	2	0	1	0

Table A3. Cont.

Disorder	Score (0–3)	Screening			
		Availability		Performance	
		DBS Test Is Available and in Use	DBS Test Is Not Yet Available, but Is in Development with Published Evidence	DBS Test Has a Low False-Positive Rate or a High Positive Predictive Value	DBS Test Has a High False-Positive Rate or a Low PPV, or Additional Confirmatory Strategies Are Required That Are Available to Improve Screening Performance
		OR	OR	OR	OR
		2	1	1	0.5
Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)	3	2	0	1	0
Isovaleric acidaemia (IVA)	3	2	0	1	0
Maple syrup urine disease (MSUD)	3	2	0	1	0
Methylmalonic acidaemia (methylmalonyl-CoA mutase) (MUT)	3	2	0	1	0
Carnitine palmitoyltransferase, type II deficiency (CPT II)	3	2	0	1	0
Batten disease (CLN2)	2	0	1	1	0
Niemann Pick A/B (ASM deficiency)	3	2	0	1	0
Trifunctional protein deficiency (TFP)	3	2	0	1	0
Gaucher disease	2.5	2	0	0	0.5
Lysosomal acid lipase deficiency (LAL-D/Wolman/CESD)	3	2	0	1	0
Multiple acyl-CoA dehydrogenase deficiency (MADD)	3	2	0	1	0
MPS VI (Maroteaux-Lamy syndrome)	1.5	0	1	0	0.5
Alpha-mannosidosis	2	0	1	1	0
Fabry disease	2.5	2	0	0	0.5
MPS II (Hunter syndrome)	1.5	0	1	0	0.5
MPS III (Sanfilippo syndrome)	2	0	1	1	0
Niemann-Pick type C disease	1	0	1	0	0
MPS IV (Morquio syndrome)	1.5	0	1	0	0.5
Sandhoff disease (GM2 gangliosidosis, type II)	0	0	0	0	0
Farber disease	0	0	0	0	0
Tay-Sachs disease (GM2 gangliosidosis, type I)	0	0	0	0	0
MPS VII (Sly syndrome)	0	0	0	0	0
MPS IX (hyaluronidase deficiency)	0	0	0	0	0

Table A4. Scoring of IMDs using the NBS evaluation algorithm: pillar *Treatment*.

Disorder	Score (0–4)	Treatment								
		Availability				Outcomes				
		An EMA-Approved Therapy Is Available	A Therapeutic Strategy Is Available (Diet, HSCT, BMT)	A Therapy Is in Late Development (Phase 3)	A Therapy Is in Early Development (Preclinical, Phase 1, or Phase 2)	The Therapeutic Strategy Changes the Prognosis for All Forms of the Condition	The Therapeutic Strategy Changes the Prognosis Only for Some Forms of the Condition	The Therapeutic Strategy Does Not Change Prognosis or Improves Only Some Symptoms	Pre-Symptomatic Initiation Results in Better Outcomes	
		OR	OR	OR	OR	OR	OR	AND		
		1.5	1	1	0.5	1.5	1	0.5	1	
Carnitine uptake defect/carnitine transport defect (CUD)	4	1.5	0	0	0	1.5	0	0	1	
Severe combined immunodeficiency (SCID)	3.5	1.5	0	0	0	0	1	0	1	
Glutaric aciduria type 1 (GA1)	3	0	1	0	0	0	1	0	1	
Homocystinuria (HCU)	4	1.5	0	0	0	1.5	0	0	1	
Phenylketonuria (PKU)	4	1.5	0	0	0	1.5	0	0	1	
Tyrosinemia, type 1 (TYR 1)	4	1.5	0	0	0	1.5	0	0	1	
Classic galactosaemia (GALT)	3	0	1	0	0	0	1	0	1	
3-Hydroxy-3-methylglutaric aciduria (HMG)	3.5	0	1	0	0	1.5	0	0	1	
Pompe disease	4	1.5	0	0	0	1.5	0	0	1	
X-linked adrenoleukodystrophy (X-ALD)	3	0	1	0	0	0	1	0	1	
Argininosuccinic aciduria (ASA)	3	1.5	0	0	0	1.5	0	0	0	
Carnitine palmitoyltransferase, type I deficiency (CPT I)	3.5	0	1	0	0	1.5	0	0	1	
Long-chain 3 hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)	2.5	0	1	0	0	0	0	0.5	1	
Methylmalonic acidaemia (cobalamin disorders, Cbl A, B)	3.5	0	1	0	0	1.5	0	0	1	
Metachromatic leukodystrophy (MLD)	3.5	1.5	0	0	0	0	1	0	1	

Table A4. Cont.

Disorder	Score (0–4)	Treatment							
		Availability				Outcomes			
		An EMA-Approved Therapy Is Available	A Therapeutic Strategy Is Available (Diet, HSCT, BMT)	A Therapy Is in Late Development (Phase 3)	A Therapy Is in Early Development (Preclinical, Phase 1, or Phase 2)	The Therapeutic Strategy Changes the Prognosis for All Forms of the Condition	The Therapeutic Strategy Changes the Prognosis Only for Some Forms of the Condition	The Therapeutic Strategy Does Not Change Prognosis or Improves Only Some Symptoms	Pre-Symptomatic Initiation Results in Better Outcomes
		OR	OR	OR	OR	OR	OR	AND	
Mucopolysaccharidosis, type I (MPS I)	3	1.5	1	1	0.5	1.5	1	0.5	1
Propionic acidaemia (PROP)	4	1.5	0	0	0	1.5	0	0	1
Biotinidase deficiency (BIOT)	3.5	0	1	0	0	1.5	0	0	1
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	2.5	0	1	0	0	1.5	0	0	0
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)	2.5	0	1	0	0	1.5	0	0	0
Citrullinemia, type I (CIT)	4	1.5	0	0	0	1.5	0	0	1
Holocarboxylase synthetase deficiency (MCD)	3.5	0	1	0	0	1.5	0	0	1
Krabbe disease	2.5	0	1	0	0	0	0	0.5	1
Argininaemia (ARG)	3.5	0	1	0	0	1.5	0	0	1
Carnitine acylcarnitine translocase deficiency (CACT)	3.5	0	1	0	0	1.5	0	0	1
Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)	2	0	1	0	0	0	1	0	0
Isovaleric acidaemia (IVA)	3	0	1	0	0	0	1	0	1
Maple syrup urine disease (MSUD)	3.5	0	1	0	0	1.5	0	0	1
Methylmalonic acidaemia (methylmalonyl-CoA mutase) (MUT)	3	0	1	0	0	0	1	0	1
Carnitine palmitoyltransferase, type II deficiency (CPT II)	3.5	0	1	0	0	1.5	0	0	1

References

1. Ferreira, C.R.; Rahman, S.; Keller, M.; Zschocke, J.; ICIMD Advisory Group. An International Classification of Inherited Metabolic Disorders (ICIMD). *J. Inherit. Metab. Dis.* **2021**, *44*, 164–177. [[CrossRef](#)] [[PubMed](#)]
2. Ferreira, C.R.; van Karnebeek, C.D.M.; Vockley, J.; Blau, N. A Proposed Nosology of Inborn Errors of Metabolism. *Genet. Med.* **2019**, *21*, 102–106. [[CrossRef](#)] [[PubMed](#)]
3. George, R.S.; Moat, S.J. Effect of Dried Blood Spot Quality on Newborn Screening Analyte Concentrations and Recommendations for Minimum Acceptance Criteria for Sample Analysis. *Clin. Chem.* **2016**, *62*, 466–475. [[CrossRef](#)] [[PubMed](#)]
4. Loeber, J.G.; Platis, D.; Zetterström, R.H.; Almashanu, S.; Boemer, F.; Bonham, J.R.; Borde, P.; Brincat, I.; Cheillan, D.; Dekkers, E.; et al. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. *Int. J. Neonatal Screen.* **2021**, *7*, 15. [[CrossRef](#)] [[PubMed](#)]
5. la Marca, G. La organización del cribado neonatal en Italia: Comparación con Europa y el resto del mundo. *Rev. Esp. Salud Pública* **2021**, *95*, 26.
6. Cornel, M.; Rigter, T.; Weinreich, S.; Burgard, P.; Hoffmann, G.F.; Lindner, M.; Loeber, J.G.; Rupp, K.; Taruscio, D.; Vittozzi, L. Evaluation of Population Newborn Screening Practices for Rare Disorders in Member States of the European Union. Newborn Screening in Europe; Expert Opinion Document. EU Network of Experts on Newborn Screening. 2011. Available online: <https://isns-neoscreening.org/wp-content/uploads/2016/06/Expert-opinion-document-on-NBS-FINAL.pdf> (accessed on 21 June 2021).
7. Castiñeras, D.E.; Couce, M.-L.; Marin, J.L.; González-Lamuño, D.; Rocha, H. Newborn screening for metabolic disorders in Spain and worldwide. *An. Pediatr.* **2019**, *91*, 128.e1–128.e14. [[CrossRef](#)]
8. Burlina, A.; Jones, S.A.; Chakrapani, A.; Church, H.J.; Heales, S.; Wu, T.H.Y.; Morton, G.; Roberts, P.; Sluys, E.F.; Cheillan, D. A new approach to objectively evaluate inherited metabolic diseases for inclusion on newborn screening programmes. *Int. J. Neonatal Screen.* **2022**, *8*, 25.
9. Wilson, J.M.; Jungner, Y.G. Principles and practice of mass screening for disease. *Bol. Oficina Sanit. Panam.* **1968**, *65*, 281–393.
10. Watson, M.S.; Mann, M.Y.; Lloyd-Puryear, M.A.; Rinaldo, P.; Howell, R.R. Newborn Screening: Toward a Uniform Screening Panel and System. *Genet. Med.* **2006**, *8* (Suppl. 1), 1S–252S. [[CrossRef](#)]
11. OECD iLibrary. Available online: <https://www.oecd-ilibrary.org/> (accessed on 1 July 2021).
12. Loeber, J.G. Neonatal Screening in Europe; the Situation in 2004. *J. Inherit. Metab. Dis.* **2007**, *30*, 430–438. [[CrossRef](#)]
13. Loeber, J.G.; Burgard, P.; Cornel, M.C.; Rigter, T.; Weinreich, S.S.; Rupp, K.; Hoffmann, G.F.; Vittozzi, L. Newborn Screening Programmes in Europe; Arguments and Efforts Regarding Harmonization. Part 1. From Blood Spot to Screening Result. *J. Inherit. Metab. Dis.* **2012**, *35*, 603–611. [[CrossRef](#)]
14. United Kingdom National Screening Committee. Screening in the UK: Making Effective Recommendations 1 April 2018 to 31 March 2019. Page Last Updated on 30 July 2021. Available online: <https://www.gov.uk/government/publications/uk-national-screening-committee-recommendations-annual-report/screening-in-the-uk-making-effective-recommendations-1-april-2018-to-31-march-2019> (accessed on 4 September 2021).
15. Sonnet Study. Heel Nederland Screent Straks Op SCID! The Whole of The Netherlands Will Soon Be Screening for SCID! Available online: <http://sonnetstudie.nl/heel-nederland-screent-straks-op-scid> (accessed on 5 January 2021).
16. Burlina, A.B.; Polo, G.; Salviati, L.; Duro, G.; Zizzo, C.; Dardis, A.; Bembi, B.; Cazzorla, C.; Rubert, L.; Zordan, R.; et al. Newborn Screening for Lysosomal Storage Disorders by Tandem Mass Spectrometry in North East Italy. *J. Inherit. Metab. Dis.* **2018**, *41*, 209–219. [[CrossRef](#)] [[PubMed](#)]
17. Martínez-Morillo, E.; Prieto García, B.; Álvarez Menéndez, F.V. Challenges for Worldwide Harmonization of Newborn Screening Programs. *Clin. Chem.* **2016**, *62*, 689–698. [[CrossRef](#)] [[PubMed](#)]
18. National Institute of Neurological Disorders and Stroke. Batten Disease Fact Sheet. Page Last Updated on 13 March 2020. Available online: <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Batten-Disease-Fact-Sheet> (accessed on 1 July 2021).
19. Almannai, M.; Alfadhel, M.; El-Hattab, A.W. Carnitine Inborn Errors of Metabolism. *Molecules* **2019**, *24*, 3251. [[CrossRef](#)] [[PubMed](#)]
20. Zielonka, M.; Kölker, S.; Gleich, F.; Stützenberger, N.; Nagamani, S.C.S.; Gropman, A.L.; Hoffmann, G.F.; Garbade, S.F.; Posset, R.; Urea Cycle Disorders Consortium (UCDC) and the European Registry and Network for Intoxication type Metabolic Diseases (E-IMD) Consortium Study Group. Early Prediction of Phenotypic Severity in Citrullinemia Type 1. *Ann. Clin. Transl. Neurol.* **2019**, *6*, 1858–1871. [[CrossRef](#)] [[PubMed](#)]
21. Wasim, M.; Awan, F.R.; Khan, H.N.; Tawab, A.; Iqbal, M.; Ayesha, H. Aminoacidopathies: Prevalence, Etiology, Screening, and Treatment Options. *Biochem. Genet.* **2018**, *56*, 7–21. [[CrossRef](#)] [[PubMed](#)]
22. Bessey, A.; Chilcott, J.; Pandor, A.; Paisley, S. The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism. *Int. J. Neonatal Screen.* **2020**, *6*, 93. [[CrossRef](#)] [[PubMed](#)]
23. Therrell, B.L.; Padilla, C.D.; Loeber, J.G.; Kneisser, I.; Saadallah, A.; Borrajo, G.J.C.; Adams, J. Current Status of Newborn Screening Worldwide: 2015. *Semin. Perinatol.* **2015**, *39*, 171–187. [[CrossRef](#)]
24. Merritt, J.L.; Norris, M.; Kanungo, S. Fatty Acid Oxidation Disorders. *Ann. Transl. Med.* **2018**, *6*, 473. [[CrossRef](#)]

25. Almási, T.; Guey, L.T.; Lukacs, C.; Csetneki, K.; Vokó, Z.; Zelei, T. Systematic Literature Review and Meta-Analysis on the Epidemiology of Methylmalonic Acidemia (MMA) with a Focus on MMA Caused by Methylmalonyl-CoA Mutase (Mut) Deficiency. *Orphanet J. Rare Dis.* **2019**, *14*, 84. [[CrossRef](#)]
26. Zelei, T.; Csetneki, K.; Vokó, Z.; Siffel, C. Epidemiology of Sanfilippo Syndrome: Results of a Systematic Literature Review. *Orphanet J. Rare Dis.* **2018**, *13*, 53. [[CrossRef](#)]
27. Khan, S.A.; Peracha, H.; Ballhausen, D.; Wiesbauer, A.; Rohrbach, M.; Gautschi, M.; Mason, R.W.; Giugliani, R.; Suzuki, Y.; Orii, K.E.; et al. Epidemiology of Mucopolysaccharidoses. *Mol. Genet. Metab.* **2017**, *121*, 227–240. [[CrossRef](#)] [[PubMed](#)]
28. Imundo, L.; Leduc, C.A.; Guha, S.; Brown, M.; Perino, G.; Gushulak, L.; Triggs-Raine, B.; Chung, W.K. A Complete Deficiency of Hyaluronoglucosaminidase 1 (HYAL1) Presenting as Familial Juvenile Idiopathic Arthritis. *J. Inherit. Metab. Dis.* **2011**, *34*, 1013–1022. [[CrossRef](#)] [[PubMed](#)]
29. Valayannopoulos, V.; Nicely, H.; Harmatz, P.; Turbeville, S. Mucopolysaccharidosis VI. *Orphanet J. Rare Dis.* **2010**, *5*, 5. [[CrossRef](#)] [[PubMed](#)]
30. Almási, T.; Guey, L.T.; Lukacs, C.; Csetneki, K.; Vokó, Z.; Zelei, T. Systematic Literature Review and Meta-Analysis on the Epidemiology of Propionic Acidemia. *Orphanet J. Rare Dis.* **2019**, *14*, 40. [[CrossRef](#)] [[PubMed](#)]
31. EMA. EU/3/15/1508: Orphan Designation for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency. Available online: <https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151508> (accessed on 1 July 2021).
32. Turk, B.R.; Theda, C.; Fatemi, A.; Moser, A.B. X-Linked Adrenoleukodystrophy: Pathology, Pathophysiology, Diagnostic Testing, Newborn Screening and Therapies. *Int. J. Dev. Neurosci.* **2020**, *80*, 52–72. [[CrossRef](#)] [[PubMed](#)]
33. Ferreira, C.R.; Gahl, W.A. Lysosomal Storage Diseases. *Transl. Sci. Rare Dis.* **2017**, *2*, 1–71. [[CrossRef](#)]